항생제 Fluoroquinolones의 약동학 및 약력학에 관한 최신 정보 = Current Updates in Pharmacokinetics and Pharmacodynamics of Fluoroquinolones

다국어 초록 (Multilingual Abstract)

The ultimate goal of antimicrobial treatment is to decrease the morbidity and mortality related to infection. Maximizing these outcomes requires an understanding of the complex interactions between the drug administered, the host, and the infecting pathogen. Pharmacokinetics, which deals with the disposition of a drug in the body, focuses on such parameters as absorption, distribution, and elimination. Pharmacodynamics more specifically focuses on the interaction between the drug concentration at the site of action over time and the resulting antimicrobial effect. Use of quinolones has increased in vitro activity against several important pathogenic organisms as well as augmented pharmacokinetic parameters. These properties result in enhanced pharmacodynamic characteristics and should improve therapeutic outcomes against selected pathogens. In this article the pharmacokinetics and pharmacodynamic potential of these quinolones, particularly fluoroquinolones, is reviewed.

참고문헌 (Reference)

1 Quintiliani R, "Using pharmacodynamic and pharmacokinetic concepts to optimize treatment of infectious diseases" 21 : 219-232, 2004

2 Andriole VT, "The quinolones: past, present, and future" 41 (41): S113-S119, 2005

3 O'Donnell JA, "The newer fluoroquinolones" 18 : 691-716, 2004

4 Johnson RD, "The effect of sparfioxacin on the pharmacokinetics of theophylline at steady-state conditions" 35 : 936-, 1995

5 Mehlhorn AJ, "Safety concerns with fluoroquinolones" 41 : 1859-1866, 2007

6 Montay G, "Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800mg" 34 : 1071-1076, 1994

7 Dandekar PK, "Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion" 23 : 988-991, 2003

8 Nakashima M, "Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers" 39 : 170-174, 1995

9 Child J, "Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin" 39 : 513-515, 1995

10 Teng R, "Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers" 36 : 385-394, 1995

11 Stein GE, "Pharmacokinetics and pharmacodynamics of newer fluoroquinolones" 23 (23): S19-S24, 1996

12 Johnson JH, "Pharmacokinetics and inflammatory fluid penetration of sparfloxacin" 36 : 2444-2446, 1992

13 Craig WA, "Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men" 26 : 1-10, 1998

14 MacGowan AP, "Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection" 45 : 2916-2921, 2001

15 Child J, "Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid" 39 : 2749-2751, 1995

16 Tanaka M, "Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide" 37 : 2173-2178, 1993

17 Jacoby GA, "Mechanisms of resistance to quinolones" 41 (41): S120-S126, 2005

18 Davis R, "Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy" 47 : 677-700, 1994

19 Mueller M, "Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC" 48 : 369-377, 2004

20 Radandt JM, "Interactions of fluoroquinolones with other drugs: mechanisms, variability,clinical significance, and management" 14 : 272-284, 1992

21 Barton TD, "High rate of coadministration of di- or tri-valent cationcontaining compounds with oral fluoroquinolones: risk factors and potential implications" 26 : 93-99, 2005

22 Tanimura H, "Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116" 49 (49): 341-343, 1995

23 Flor S, "Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin" 34 : 2436-2438, 1990

24 Shiba K, "Effects of antacid on absorption and excretion of new quinolones" 49 (49): 360-361, 1995

25 Cohen KA, "Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance" 29 : 975-977, 2008

26 Ambrose PG, "Clinical pharmacodynamics of quinolones" 17 : 529-543, 2003

27 Wispelwey B, "Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones" 41 (41): S127-S135, 2005

28 Matsuda S, "Clinical experience with OPC-17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC-17116 in Gynaecology" 49 (49): 395-398, 1995

29 Grant EM, "Clinical efficacy and pharmacoeconomics of a continuousinfusion piperacillin-tazobactam program in a large community teaching hospital" 22 : 471-483, 2002

30 Ball P, "Adverse drug reactions: implications for the development of fluoroquinolones" 51 (51): 21-27, 2003

31 Borner K, "A metabolite of sparfloxacin in urine" 45 (45): S303-S304, 1993